Key Takeaway: The article discusses a poster presentation by Caldwell et al. at the 2024 Keystone Conference on Neurodegenerative Diseases. The research focuses on characterizing human iPSC-derived neurons as an in vitro model to investigate the functions of sigma-2 receptors. This innovative approach may contribute to understanding neurodegenerative diseases.
Price reaction · baseline $1.95 (2024-05-31 close) · hit pre-market · clean, no other CGTX news in the window
day 0 close · peak
+2.6%
Market Sentiment Analysis
POSITIVE FACTORS
Presentation at a prominent conference highlights research significance.
Focus on innovative in vitro models for studying receptor functions.
Potential implications for neurodegenerative disease research.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+35%
120-day peak, hindsight
Typical move
8.3%
average across 6 past catalysts
Cash runway
~33 mo
Minimal dilution risk
Lead asset
Oxytocin
Phase 2 · Oxidative Stress
Full Press Release Details
Caldwell J, Cho E, Caggiano AO, DiCaro V, Hamby ME. Characterization of Human iPSC-derived Neurons as an In Vitro Model to Investigate Sigma-2 Receptor Functions . Poster presented at 2024 Keystone Conference on Neurodegenerative Diseases .
Frequently Asked Questions
What was presented at the 2024 Keystone Conference?
A poster on characterizing human iPSC-derived neurons to study sigma-2 receptor functions.
Who conducted the research on iPSC-derived neurons?
The research was conducted by Caldwell J, Cho E, Caggiano AO, DiCaro V, and Hamby ME.
What is the focus of the research presented?
The focus is on using iPSC-derived neurons as an in vitro model for sigma-2 receptor functions.